drugset / Trial / NCT03486392
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo after 26 weeks of treatment on the percent change in body weight from baseline and to assess the safety and tolerability, in non-diabetic severely obese participants.
Timeline
- Start
- 2018-03-26
- Primary completion
- 2019-03-08
- Completion
- 2019-03-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-64565111 | Unknown | — | Subcutaneous |
| Comparator | Liraglutide | Peptide | 3 mg | Subcutaneous |